Axsome Therapeutics (STU:19X) Float Percentage Of Total Shares Outstanding: 63.86% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:19X Axsome Therapeutics Inc STU:19X
58 GF Score
Price €199.95
GF Value €196.69
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics Float Percentage Of Total Shares Outstanding?

Axsome Therapeutics STU:19X -7.00% 58 Float Percentage Of Total Shares Outstanding is 63.86% as of Jul. 14, 2026. GuruFocus rates STU:19X with a GF Score™ of 58/100 and a GF Value™ of €196.69 (Fairly Valued). The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Axsome Therapeutics's float shares is 32.86 Mil. Axsome Therapeutics's total shares outstanding is 51.46 Mil. Axsome Therapeutics's float percentage of total shares outstanding is 63.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Axsome Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Axsome Therapeutics's Institutional Ownership is 47.91%.

STU:19X
58GF Score
Axsome Therapeutics Inc STU:19X
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Axsome Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=32.86/51.46
=63.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 63.86% mean?
Axsome Therapeutics (STU:19X) has a Float Percentage Of Total Shares Outstanding of 63.86% as of Jul. 14, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Axsome Therapeutics' current Float Percentage Of Total Shares Outstanding is 63.86%. Overall, Axsome Therapeutics has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Float Percentage Of Total Shares Outstanding compare to MDGL and IONS?
Axsome Therapeutics' Float Percentage Of Total Shares Outstanding of 63.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Float Percentage Of Total Shares Outstanding is 63.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (STU:19X) is currently considered Fairly Valued. The stock's GF Value™ is €196.69, compared to a current price of €199.95 — trading 1.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 63.86%. Axsome Therapeutics' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Axsome Therapeutics (STU:19X), the current Float Percentage Of Total Shares Outstanding is 63.86% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (STU:19X) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €199.95 is trading 1.7% above its estimated GF Value™ of €196.69. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for STU:19X:

  • Float Percentage Of Total Shares Outstanding: 63.86%
  • GF Value™: €196.69 vs. price of €199.95 (1.7% above fair value)
  • GF Score™: 58/100 with 1 warning sign

No single metric tells the full story. See the STU:19X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Other Exchanges AXSM:USA1AXSM:Italy0HKF:UK
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
58GF Score

Get the complete analysis for STU:19X

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€199.95
Price
€196.69
GF Value